Clinical Pharmacology in Drug Development (CPDD) is an international, peer-reviewed, online publication of the ACCP focused on publishing high-quality clinical pharmacology studies in drug development. https://bit.ly/39XjxMS @Wiley Clinical Health

Incredibly proud of our safety team for creating this brochure, so much labor went into it!!🥳 It is a FANTASTIC read for anyone interested in learning more about pre-clinical safety assessments, and we’ve even included a few related case studies at the end of the document. Click the link in the post to download the free PDF

Late-stage safety findings can derail promising drug candidates. Download De-Risking Drug Candidates Through Modernized In Vitro Safety Pharmacology to learn how today's approaches to secondary pharmacology can help identify risks earlier and improve decision-making across discovery programs. Inside: ✔️ Strategies for aligning safety screening with project goals ✔️ A clear overview of the latest 2024 recommendations for expanded target coverage ✔️ How AI-driven visualization tools can turn complex data into actionable insights Download the guide: https://lnkd.in/dBS9jhZK #DrugDiscovery #SafetyPharmacology #SAFETYscan #SafetyScreen #EurofinsDiscovery

A partial agonist isn’t a “weak” agonist. It’s one of the most common misconceptions in pharmacology. Partial agonists often have high receptor affinity but lower intrinsic activity, allowing them to activate receptors without producing a maximal response. That single concept explains why drugs like buprenorphine, aripiprazole, and varenicline behave so differently from full agonists. As our understanding of GPCR pharmacology evolves, recent research is also exploring why partial agonists behave this way at the molecular level—knowledge that could shape the next generation of safer therapeutics. (ACS Publications) Recent reading: • Structural Determinants of Buprenorphine Partial Agonism at the μ-Opioid Receptor (J Chem Inf Model, 2025) (ACS Publications⁠) • Insurmountable Antagonism of Human μ-Opioid Receptors by Buprenorphine (Eur J Pharmacol, 2025) (ScienceDirect⁠) #Pharmacology #PharmD #Medicine #MedicalEducation #ClinicalPharmacology #Healthcare #Pharmacist #Pharmacy

The Power of 1 + 1 = 3: Understanding Drug Synergism In pharmacology, we are taught that combination therapy is often more effective than mono therapy. But why? The answer often lies in Drug Synergism. Synergism occurs when two or more drugs interact in a way that their combined effect is greater than the sum of their individual effects. It is not just about "more medicine"; it is about precision, efficiency, and clinical outcomes. Why does this matter in clinical practice? 1.Enhanced Efficacy:By targeting different pathways in a disease process simultaneously, we can achieve results that a single agent simply cannot reach. 2.Dose Reduction: Synergistic combinations can often allow for lower dosages of individual drugs. This is crucial for minimizing dose-dependent side effects and toxicity. 3.Overcoming Resistance:In fields like oncology and infectious disease, synergism is a primary tool to bypass resistance mechanisms that render single treatments ineffective. The Clinical Caveat: The "Other" Side of Interactions While synergy is a powerful goal, it is vital to distinguish it from antagonism , where drugs work against each other or unintended additive toxicity. Clinical decision-making requires a deep understanding of pharmacokinetics and pharmacodynamics to ensure we are creating a therapeutic benefit, not a safety risk. As we continue to advance in personalized medicine, identifying novel synergistic combinations will be a cornerstone of improving patient outcomes and quality of life. I’d love to hear from my network:How have you seen the principles of synergism impact your field or current research? Let’s discuss in the comments below. #Pharmacology #ClinicalResearch #HealthcareInnovation #Medicine #DrugDevelopment #Synergy #ScienceCommunication

We are pleased to share our latest publication in Frontiers in Pharmacology. Our systematic review evaluated the available evidence on the antimicrobial activity of Euphorbia hirta against priority ESKAPE pathogens-bacteria responsible for many multidrug-resistant healthcare-associated infections. By synthesizing findings from 27 in vitro studies, we found that E. hirta demonstrates promising antibacterial activity, with some studies reporting antibiotic-potentiating effects. However, the current evidence remains preclinical, highlighting the need for standardized phytochemical characterization, mechanistic validation, and well-designed in vivo studies before clinical translation. We hope this review provides a valuable evidence base for researchers working in antimicrobial resistance, natural product drug discovery, and One Health. 📖 Read the full article: https://lnkd.in/dwpQt_ne #AntimicrobialResistance #AMR #NaturalProducts #MedicinalPlants #ESKAPE #Microbiology #DrugDiscovery #Pharmacology #OneHealth #ICMR #Research #FrontiersInPharmacology #ICMR #ICMR-NITM

Q&A: How UW researchers are using AI to speed up drug discovery and development Housed in the UW School of Pharmacy, the Institute for Innovations in Drug Delivery and Disposition (I2D3) brings together experts in artificial intelligence, drug discovery, pharmacology, data science and biotechnology to ease the bottleneck between promising molecules and successful drugs. https://lnkd.in/gR3uWvBg

𝗪𝗲 𝗮𝗿𝗲 𝘆𝗼𝘂𝗿 𝗽𝗿𝗲𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗽𝗮𝗿𝘁𝗻𝗲𝗿. 𝗪𝗵𝘆 𝗧𝗿𝗶𝗮𝗹𝘀 𝟯𝟲𝟬? Iron deficiency remains a major global health concern, requiring effective and research-backed therapeutic solutions. At Trials 360, we provide comprehensive preclinical services to support iron deficiency research and early stage drug development. 𝗢𝘂𝗿 𝗽𝗿𝗲𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘀𝗲𝗿𝘃𝗶𝗰𝗲𝘀 𝗶𝗻𝗰𝗹𝘂𝗱𝗲: 1. In vivo model development and study design Customized model development and protocol design 2. Safety, efficacy, and toxicology studies 3. Pharmacokinetic and pharmacodynamic study support 4. Data analysis, interpretation, and study optimization DRF and MTD studies 5. Scientific reporting and medical writing At Trials 360, we help bridge early research with meaningful therapeutic advancement. 𝗖𝗼𝗻𝘁𝗮𝗰𝘁 𝗨𝘀 🌐 www.trials360.com 📧 bd@trials360.com #PreclinicalResearch #IronDeficiencyResearch #Trials360

When I first connected with GCCL during the EW Biopharma Summit, a clear strategic vision immediately came to mind. I realized that by combining GemPharmatech’s world-class in vivo pharmacology platforms with GCCL’s top-tier clinical sample analysis capabilities, we could build a seamless, truly integrated 'One-Stop Solution' for global biopharma clients transitioning from bench to clinic. Following our initial discussions to spark this collaboration, the partnership reached another exciting milestone with a successful executive meeting at GemPharmatech’s San Diego office. Although I couldn't be there in person this time, it is incredibly rewarding as a BD manager to see the partnership I initially envisioned and initiated successfully progress onto the global executive stage, shaping into a powerful alliance. Moving far beyond a simple connection, I am truly excited for the 'next chapters' of our journey with GCCL as we create synergistic value for the global biotech ecosystem. A huge thank you to both teams for driving this vision forward! 🚀

I am delighted to share that our research paper has been successfully published in the International Journal of Drug Delivery Technology (IJDDT). 📝 Title: Elucidation of Dioscorea alata Peel as a Multi-Target Neuroprotective Agent Against Alzheimer's Disease Using Network Pharmacology, Molecular Docking, and ADMET Analysis 🔬 Research Highlights: • Investigated the neuroprotective potential of Dioscorea alata peel phytoconstituents against Alzheimer's disease. • Applied Network Pharmacology, Molecular Docking, and ADMET Analysis for comprehensive in-silico evaluation. • Identified Apigenin and Quercetin as promising lead compounds targeting key Alzheimer's-related proteins. • Demonstrated potential modulation of the PI3K–Akt, MAPK, and apoptosis signaling pathways. 📚 Journal: International Journal of Drug Delivery Technology (IJDDT) 📅 Published: May 2026 I sincerely thank my guide Dr. Omprakash Bhusnure, co-authors and Channabasweshwar Pharmacy College for their continuous support and encouragement throughout this research journey. Looking forward to contributing further to pharmaceutical research and drug discovery. #ResearchPublication #PharmaceuticalResearch #AlzheimersDisease #NetworkPharmacology #MolecularDocking #ADMET #DrugDiscovery #Neuroprotection #MPharm #ResearchScholar #IJDDT #Pharmacy #LifeSciences